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Abstract
Alzheimer’s disease (AD) affects over 5 million individuals in the United States annually. By
the year 2050, the number of individuals living with AD is projected to triple (Latest
Alzheimer’s Facts and Figures, 2016). Although there is no cure for AD, there are many
prescriptive pharmacologic agents used to help manage the clinical manifestations of the disease.
Complementary and alternative medicines (CAM) and herbal supplements are also used in the
treatment of AD, however indications for their use and effectiveness during the progression of
AD have not been examined. The purpose of this study was to examine the use of herbal
supplements in managing the clinical manifestations of AD. The secondary purpose was to
compare a variety of herbal supplements used to treat the clinical manifestations of AD and to
evaluate the most widely used and most beneficial for clinical practice. A literature review
examining herbal supplements and their risks, benefits, and uses in AD was conducted from
multiple online databases. Peer reviewed articles published in the English language from 19982016 that focused on herbal supplements used to control the clinical manifestations of mild to
severe AD were included for synthesis. Results from 14 studies that used herbal supplements as a
treatment for the clinical manifestations of AD were compared for effectiveness in the
management of symptoms. The findings suggest Ginkgo Biloba is the most effective and widely
used herbal supplement in the treatment for cognitive decline in AD. Other supplements
including Saffron, Curcumin, Cistanches Herba, and Sage were found to improve memory
function and activities of daily living in individuals with AD. Herbal supplements can be cost
effective and easier to retrieve for many individuals in comparison with prescriptive drug
therapy. Although the research demonstrated beneficial results with the use of herbal
iii

supplements, the limitations of these studies make the application of the results problematic.
Therefore, further research in this area is required.
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Introduction
Alzheimer’s disease (AD) affects over 5 million individuals in the United States
annually. Due to the older generation population growing, by the year 2050, the number of
individuals living with AD is projected to triple. (Latest Alzheimer’s Facts and Figures, 2016).
Although there is no cure for AD, there are many prescriptive pharmacologic agents used to help
manage the clinical manifestations of the disease. Agents used to treat AD include
cholinesterase inhibitors, antidepressants, antipsychotics, tricyclic antidepressants, and
benzodiazepines. These pharmacologic agents lessen memory loss and confusion, and treat mood
and sleep changes. Complementary and alternative medicines (CAM) and supplements are also
used in the treatment of AD, however indications for their use and effectiveness during the
progression of AD have not been examined.
Although prescriptive pharmacologic therapy is widely used by individuals for the
treatment and management of AD, the use of herbal supplements in relation to AD is not widely
studied. Over–the-counter, herbal supplements are used daily for a variety of different ailments
including; improving memory function, lowering cholesterol, preventing colds, preventing
nausea and vomiting, and lessening joint pain. Although there are herbal supplements
recommended for patients with AD, their effectiveness in regards to symptom management and
disease progression has not been established. Most studies conducted on the use of herbal
supplements and their effectiveness at managing the clinical manifestation of AD have been
based on testimonials and small sample sizes, indicating the need for further research.

1

Problem
Clinical manifestations of AD are often debilitating and difficult to control. Although
pharmacological therapy is the most widely prescribed and used treatment plan for controlling
the signs and symptoms of AD, some individuals prefer complementary and alternative therapies
for a variety of reasons. There is a lack of evidence to support the use of herbal supplements on
managing the clinical manifestations of AD as a solo therapy or in concurrence with prescribed
agents. Herbal supplements must be further evaluated to better understand the risks and benefits
as agents used for relief of the clinical manifestations of AD.
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Purpose
The purpose of this literature review is to examine the use and effectiveness of herbal
supplements and their benefits on minimizing clinical manifestations of AD. There is insufficient
research to show herbal supplements have a positive and significant effect on the clinical
manifestations of AD. There is also a lack of evidence on when herbal supplements should be
included as part of an individual’s therapy and how early herbal supplements should be started in
treating the manifestations of the disease as it progresses in symptom severity. Most of the
research has been based on small sample sizes and inconsistently designed research methods,
yielding mixed or insignificant results.
Understanding the benefits of herbal supplement use for controlling the clinical
manifestations of AD can provide options for an individual’s course of treatment, either as solo
therapy or as an adjuvant to prescriptive therapy. Research is needed to educate individuals with
AD about different herbal and drug therapy options they can use to help control certain clinical
manifestations of the condition, including memory loss and sleep disturbances. Individuals may
prefer CAM treatments over pharmacologic treatments, so healthcare providers must obtain the
knowledge on herbal supplements and their safety and effectiveness to help aid individuals in the
right direction of treatment.
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Method
A literature review was performed using research articles available from 1995 to 2016
regarding the use of herbal supplements and their relationship in managing clinical
manifestations of Alzheimer’s disease. The focus was mainly related to the use of herbal
supplements as drug therapy for Alzheimer’s disease. Databases that were used to search for
articles included Cumulative Index to Nursing and Allied Health Literature (CINAHL),
Educational Resources Information Center (ERIC), Elton B. Stephens Co. Host (Ebsco Host),
Medical Literature On-line (Medline), and Psychological Information Database (PsychINFO).
Searches used a combination of the following terms: Alzheimer’s, dementia*, herbal
supplement*, clinical manifestation*, symptom*, benefit*, and risk*. Inclusion criteria consisted
of 1) published research in English, 2) herbal supplements used at all stages of AD and as
adjuvant therapy to prescriptive agents, and 3) herbal supplements used in AD to control clinical
manifestation of the condition. Articles that were excluded focused on AD therapy with only
prescriptive agents and AD treatments that did not include the use of herbal supplements.
Each article was evaluated and individually critiqued for relevance to the topic and
application to the use of herbal supplements in people with dementia. In the appendices, Table 1
summarizes the findings for each article that was reviewed for this thesis. Studies in this review
include both quantitative and qualitative studies, and systematic literature reviews that were
published between 1998-2016. None of the single articles included in this research were
included in the systemic literature reviews. The studies were published in a range of different
countries, including the United States, London, the Netherlands, China, Korea, and the United

4

Arab Emirates. The data was extracted to synthesize the relationship between the benefits of
herbal supplements in controlling the clinical manifestations of AD. Subsequently, all the
critiqued articles were synthesized by the researcher, and key findings were extracted along with
consistent and inconsistent findings and gaps in the literature. Limitations of the study and
recommendations for future research also were noted.
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Background
AD, the leading cause of dementia, is a progressive, neurological disorder that destroys
brain cells, causing memory loss and dysfunction. The underlying pathophysiologic cause of AD
is not completely understood, however, research has highlighted the clinical manifestations and
expected progression of the disease. AD is thought to be caused by the buildup and degradation
of amyloid beta peptides in the brain. An increase of amyloid beta peptides causes neurologic
inflammation in the central nervous system, both in the blood brain barrier and the brain
parenchyma, resulting in neurofibrillary tangles and neuron remodeling. In addition, peripheral
immune cells also have the ability to assist in the neuro-inflammatory process in the blood brain
barrier and brain parenchyma. Research in brain injury related to AD suggest the neuroinflammatory response may lead to neurodegeneration, causing brain damage (Dá Mesquita et
al., 2016).
There is an abundance of known risk factors leading to AD. Genetics and environmental
factors can influence a diagnosis of AD in individuals that exhibit the symptoms. A leading risk
factor for AD is the expression of the ApoE ε4 allele. This allele is found in the majority of
persons with AD, and has a direct connection to the development of AD and the course of the
disease process. ApoE ε4 may also increase the severity of vascular risk factors associated with
AD. Other risk factors include high cholesterol, smoking, cognitive impairment issues, low
education levels, female gender, elevated homocysteine levels, and elevated human placental
lactogen (Panpalli Ates, Karaman, Guntekin, & Ergun, 2016). These risk factors should be
closely monitored in individuals, so the disease can be caught at an early stage. In the future,
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individuals with risk factors may be tested for the ApoE ε4 allele to help make the diagnosis.
With continuous research on the ApoE ε4 allele, researchers may be able to find better therapies
for the management of AD and for therapy that can lead to improved quality of life in individuals
suffering from the clinical manifestations of AD. In addition, further research on benefits of
herbal supplements that may affect the ApoE ε4 allele is needed to determine when this therapy
should be started in the course of AD.
AD progresses through four stages: predementia, moderate, mild, and severe.
Predementia levels can be measured by arterial spin-labelling cerebral blood flow (ASL-CBF).
Stage 1 predementia is defined as a decrease in ASL-CBF, with abnormal amyloid-β (Aβ) in
both the temporal and parietal regions in the brain. Stage 2 predementia has both abnormal Aβ
and total-tau with decreased ASL-CBF in the temporal regions of the brain (Binnewijzend et al.,
2016). As the CBF decreases, AD advances into more severe stages. After the predementia
stages, an individual will progress through multiple phases of AD. In the mild stage of AD,
individuals begin to have trouble remembering recent events, misplace items, and have a tough
time planning events. These individuals are still able to function independently, but start to
withdraw themselves from certain events and daily tasks. The moderate or middle stage of AD
begins when an individual can’t recall what day it is, or mistake people in their family for the
wrong person. The confusion and forgetfulness manifests and progressively worsens. The
individual will need assistance with certain activities of daily living. In the final stage, the severe
or late stage of AD the individual requires total care. The individual is unable to converse, and
physical abilities, including walking become a challenge. The disability will progress and result
in complications and comorbidities that will eventually lead to death. The leading cause of death
7

in AD is usually infection or respiratory failure (Alzheimer’s stages, 2015). Medications or
alternative therapies can be used at any stage in an effort to control symptoms or delay
progression, but they are not curative.
The predominant clinical manifestations of AD are progressive memory loss and changes
in mental status. These often manifest as apathy, delusions, hallucinations, anxiety, agitation, and
irritability (Tokuchi et al., 2016). Some individuals will become extremely violent, while others
prefer isolation. Due to the progressive memory loss associated with AD, recognition of people,
places, and objects becomes increasingly difficult to distinguish. For example, individuals with
later stages of AD often fail to recognize family members, or accuse loved ones of stealing.
Often times, an individual with AD has realistic delusions that their significant other is having an
affair, which leads to anger, mistrust, and frustration. AD is difficult to manage because of the
differentiating manifestations of each individual. Likewise, individual’s that are taking
prescription drug therapy or herbal supplements will often present with varying response to these
agents and the majority will show some form of AD clinical manifestations despite therapy.
Pharmacological therapies are most often used to manage the clinical manifestations of
AD. Some of the most common drugs used for AD are Acetylcholinesterase Inhibitors (AChEI),
N-Methyl-D-asparate Receptor Antagonists (NMDA), and Amyloid Binders. AChEI’s are used
to increase the brain’s cholinergic functions, and are usually well tolerated. NMDA’s work to
block the overstimulation of nitric oxide. Overstimulation of nitric oxide leads to cell death, so
NMDA’s are a common treatment individuals receive. Amyloid Binders help to prevent the
formation of Aβ senile plaques. (Mendiola-Precoma, Berumen, Padilla, & Garcia-Alcocer,
2016). Some individuals will be prescribed a combination of medications used to treat AD as
8

well as a variety of other medications to manage manifestations, including mood changes, and
sleep disturbances.
Nonpharmacological therapies, or CAM, are not as widely used to treat the clinical
manifestations of AD. However, CAM such as exercise, mental challenges, folic acid
supplements, and the Mediterranean diet have been shown to improve cognitive function in
individuals with AD (Mendiola-Precoma et al., 2016). Herbal supplements are not commonly
known for the management of AD, however certain herbal supplements may have the ability to
help prevent the start of AD, or help to manage the cognitive decline of the brain once the
disease is already diagnosed. Herbal supplements are used by many people with AD, but only
limited studies have found any statistical evidence to support their use.
The use of herbal supplements in AD and their effectiveness in controlling the clinical
manifestations of the condition is not fully understood. Although research suggests herbal
supplements can have a positive impact on the clinical manifestations of AD, much of the
research was based on small sample sizes and may not be applicable to the larger population.
There is no significant evidence to support the therapeutic benefits of herbal supplements for the
treatment of clinical manifestations of AD, such as memory loss and irritability. Although
current research provides us with mostly inconclusive results, several studies showed promising
results with certain herbal supplements, supporting the need for further research on the topic.
Herbal supplements are regulated differently than prescription pharmacologic agents,
causing many individuals to misunderstand the safety and use of herbal-based products. Herbal
supplements are often misused by individuals because they choose to self-treat instead of
consulting their provider. Individuals that use herbal supplements for their intended purpose
9

agree they are an effective and a safe means of treatment (Gray & Rutledge, 2013). Individuals
often appreciate that herbal supplements cost less than prescriptive drug therapies, and many
would prefer herbal supplements if health insurance covered the costs (Gray & Rutledge, 2013).
Individuals with AD often use herbal supplements as part of their treatment and begin
taking herbal supplements in the early stages of the disease. By beginning the herbal supplement
use in the early stages of AD, individuals hope to preserve their memory function and delay
other clinical manifestations of the disease as much as possible. In most cases, individuals that
have AD are willing to try herbal supplements in conjunction with prescriptive agents to help
control the manifestations of the disease.
Herbal supplements commonly used to treat AD include flavonoids, resveratrol, and
gingko biloba. After several small clinical trials, Flavonoids have been considered effective in
the treatment of AD and aid in protecting neurologic functions (Mendiola-Precoma et al., 2016).
Resveratrol has been shown to assist in protecting neurons from cell death and oxidation. It is an
anti-inflammatory substance, and has also been shown to promote the normal function of neural
mitochondria (Mendiola-Precoma et al., 2016). Ginkgo biloba is the most researched herbal
supplement in relation to AD. Ginkgo biloba used in combination with cholinesterase inhibitors
show a significant improvement on a mini mental state examination (MMSE) in individuals with
AD, however both gingko biloba and the cholinesterase inhibitor used alone did not show a
substantial improvement on MMSE scores (Canevelli et al., 2014). Gingko biloba is known to
have minimal side effects, and other herbs such as sage and balm have been found to have
memory improving effects as well (Perry, Pickering, Wang, Houghton, & Perry, 1998). There
are a variety of herbal supplements which may have beneficial effects for an individual with AD,
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but the lack of substantial research and knowledge related to their effectiveness and ability to
improve the quality of life in individuals with AD makes their use questionable.
Nonetheless, studies have suggested fewer sleep disturbances and improved memory
function when individuals with AD include certain herbal supplements in their treatment. One
study showed the therapeutic effect of Ginkgo Biloba had similar effects as Donepezil, which is
a pharmacologic drug that treats impairment of memory. Individuals preferred the use of Ginkgo
Biloba compared to Donepezil because it had minimal side effects compared to Donepezil (Perry
et al., 1998).
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Results
Fourteen studies related to herbal supplement effectiveness on the clinical manifestations
of AD were included in this literature review. Of the fourteen studies reviewed, five studies
solely focused on the effectiveness of herbal supplements compared to a placebo group. These
studies indicated that herbal supplements can show an improvement in individual’s cognitive
function through better scores on the short cognitive performance test (SKT), the
Neuropsychiatric inventory (NPI), Alzheimer’s Disease assessment scale-cog (ADAS-Cog), and
the Clinical-Dementia Rating scale (CDR). These citations also concluded no harm was found by
using an herbal supplement as treatment. One citation compared a sole pharmacologic treatment,
which is most often used in managing the clinical manifestations of AD, to an herbal supplement
combined with a pharmacologic treatment. This study found the group receiving the combination
treatment had a much higher Mini-mental status exam (MMSE) score compared to the solo
pharmacologic therapy. Another citation compared solo pharmacologic treatment with solo
herbal supplement treatment and both displayed similar benefits. The remaining seven citations
were based on qualitative studies and literature reviews. These studies suggested decreased
production of Aβ plaques, improvement in behavioral and cognitive decline, neuroprotective
effects, anti-oxidant effects, and improving both quality of life and activities of daily living.
Table 1 discusses the findings of the articles, which were analyzed to determine the
benefits of herbal supplements in treating the clinical manifestations of AD. The researched
examined within this thesis provides a framework of herbal supplement use in managing the
clinical manifestations of AD. Although many herbal supplements were studied, Ginkgo Biloba,
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Resveratrol, and Curcumin were the most widely researched. Ginkgo Biloba had the most
significant and reliable results for controlling the clinical manifestations of AD.
Ginkgo Biloba
Ginkgo Biloba is the most widely studied herb in relation to treating manifestations of
AD, however, mixed results regarding the effectiveness have been found. Spatial memory, one
of the deficits frequently affected in early AD, includes recognizing your hometown or the layout
of a house. Gingko biloba was found to have protective effects against spatial cognitive
impairment in early AD (Anekonda & Reddy, 2005). In another study Ginkgo Biloba was
combined with AChEI’s and was compared to solo AChEI treatment. Although the sample size
was 828, only 29 participants received the combined treatment. The combined treatment showed
a significantly higher mini-mental status examination (MMSE) score than solo drug therapy with
an AChEI, however it did not show a significant improvement in the ADAS-Cog score or
activities of daily living (ADL’s) (Canevelli et al., 2014). Furthermore, a Ginkgo Biloba
supplement of EGb 761 was studied in a trial against a placebo treatment group. The Egb 761
group showed an SKT score improvement of -1.4 and a total NPI increase of -3.2, while the
placebo group showed minimal change (Ihl et al., 2011). In two qualitative studies both showed
Ginkgo biloba to improve cognitive function in patients with AD (Mendiola-Precoma et al.,
2016) (Perry et al., 1998). A literature review examined 6 articles on Ginkgo Biloba and 5 of
these articles showed Ginkgo Biloba having a positive impact on improved cognitive functions
and activities of daily living in individuals with AD (Yang et al., 2014). Although the majority of
the studies have shown beneficial effects with the use of Ginkgo Biloba, further research is
needed to confirm these effects due to small sample studies and animal testing. Likewise, the
13

studies examining the use of Gingko biloba were limited to early onset of AD manifestations,
such as forgetfulness and spatial recognition, and did not address issues related to advanced
disease or progression of symptoms.
Curcumin
Aβ plaque accumulation noted on advanced scanning techniques, such as magnetic
resonance imaging (MRI) of the brain, is one of the main signs of AD. In a research study
involving the effects of curcumin intake in people with AD, curcumin blocked the aggregation of
Aβ1–40 and the formation of Aβ1–42 fibrils and oligomers. These substances accumulate in the
brain as individual’s age and are associated with the onset of AD. In the same research, the
accumulation of Aβ plaques was found to be reduced in aging mice (Anekonda & Reddy, 2005).
A study evaluating the effects of curcumin on mice found that the mice receiving curcumin were
able to perform better in memory task related activities, and showed improvement in
spontaneous behavior, compared to mice in the control group not receiving curcumin (Mi Hye,
Sung-Hoon, & Woong Mo, 2014). Further research in human participants could possibly
provide insight into the beneficial effects of curcumin in slowing the progression of plaque
formation in the brain.
Saffron
Saffron was shown to be safe and effective in treating certain clinical manifestations of
mild-moderate AD including fatigue, depression, and memory loss. Saffron used as the sole
treatment for AD showed significant improvement on the ADAS-Cog and CDR tests compared
to the placebo group. On both the ADAS-Cog and CDR tests, the higher the score, the higher
14

level of cognitive dysfunction is present in the individual. By week 16 of the trial, the group
receiving saffron improved by -3·69 on the ADAS-Cog and -0·67 on the CDR test. No
significant difference was found in adverse effects including dizziness, dry mouth, and nausea
between the saffron and placebo groups. These results concluded that although saffron was found
effective, it was only for short term use and needs to be further evaluated. (Akhondzadeh et al.,
2010)
Resveratrol
Resveratrol has been studied for use in a variety of conditions, including AD. Resveratrol
has been tested in both humans and rats and was found to have multiple benefits. In rats,
resveratrol prevented oxidative stress and both intracerbroventrical and straptozotocin induced
cognitive impairments. Oxidative stress is an imbalance between reactive oxygen species (ROS)
and the body’s ability to detoxify and repair the resulting damage (Anekonda & Reddy, 2005).
Oxidative stress arises early on in the process of AD, preceding the events of plaque and
neurofibrillary tangles. In human cells, resveratrol protected from ROS which keeps the body’s
normal balance preventing oxidative stress, and also prohibited DNA fragmentation (Anekonda
& Reddy, 2005). It also showed an increased life span in relation to resveratrol, however this
trial was performed on mice (Giulietti et al., 2016). Lastly, in a qualitative study resveratrol as a
supplement showed neuroprotective effects in AD. Resveratrol activates SIRT1 which is a sirtuin
that protects neurons from apoptotic process (cell death) and oxidative stress. SIRT1 also
displayed reduction of the pathway of glial cells that are unprotected from Aβ. These
neuroprotective effects help promote cell survival and the correct functioning of mitochondria.
(Mendiola-Precoma et al., 2016).
15

N-3 FA
One study that was reviewed in this literature dealt with omega-3 fatty acids and its effect
on cerebrospinal fluid in individuals with AD. This study had a small sample size (n=33) and
showed minimal cognitive benefits on individuals with mild AD. The trial on individuals with
moderate-severe AD was unsuccessful and showed no benefit (Freund Levi et al., 2014).
Cistanches Herba
Cistanches Herba is a desert plant that is said to have a positive impact on memory
function. The effects of Cistanches Herba on the clinical manifestation of AD were compared to
Donepezil (Aricept®) an AChEI commonly prescribed for AD, and no treatment for individuals
with mild-moderate AD. Cistanches Herba and Donepezil both showed close to the same
improvement in cognitive function and slowing down hippocampus atrophy. Hippocampus
atrophy is a common sign of AD and with MRI can be tracked in moderate-severe stages of AD.
At week 0, all three groups had a score of about 20 on the MMSE. The higher the score on the
MMSE, the better cognitive function the individual is displaying. By the 48th week of the study,
the herbal and pharmacologic group improved to a score of 24 while the group receiving no
treatment dropped to an 18. Moreover, the ADAS-cog scores showed less significant scores, but
still displayed improvement in the two treatment groups and a degradation of score for the group
receiving no treatment. It was also noted that Cistanches Herba is much cheaper and easier to
retrieve, so some individuals may prefer this treatment over Donepezil (Li et al., 2015).
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Others
Flavonoids were discussed in a few studies and were found to be safe, portray
neuroprotective effects, improve memory, and inhibit the production of acetylcholinesterase
(Mendiola-Precoma et al., 2016). In one study green tea extract was discovered to reverse
memory deficits by inhibiting AChEI activity (Anekonda & Reddy, 2005). Fig, which is under
the class of a polyphenol, demonstrated improvements in behavioral and cognitive function in
AD, and reduced the accumulation of Aβ (Giulietti et al., 2016). Lastly, crocus, sage, lemon
balm, and Fuzhisan were compared to either a placebo or orthodox medication and showed an
improvement in individuals with AD on the ADAS-Cog test (Yang et al., 2014). Herbs have
been used for a variety of reasons for centuries, but further studies can assist in proving their
benefits and effectiveness in the use for treating clinical manifestations of AD.
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Discussion
The studies examined for this thesis can offer insight into a complementary and
alternative treatment for individuals with AD. Research findings showed the benefits of using
herbal supplements as part of treatment for managing the clinical manifestations of AD.
Although the literature review presented mixed results, the majority of studies revealed several
positive effects that herbal supplements demonstrated in minimizing early, debilitating clinical
manifestations of AD.
Using herbal supplements as part of treatment for AD may be beneficial and cost
effective to many individuals, since herbal agents often do not cost as much as prescriptive drug
therapy. In addition, when compared to pharmacologic agents, Ginkgo Biloba was found to have
minimal side effects compared to Donepezil which has various side effects including dizziness,
nausea, vomiting, and diarrhea (Perry et al., 1998). Some individuals prefer natural and herbal
therapies compared to pharmacologic treatments, so providing information about herbal
supplements that have been effective in reducing clinical manifestations of AD is useful. With
millions of individuals being diagnosed with AD each year, and the number of individuals
continuing to rise, exploring treatment options is essential. Because AD is an incurable disorder,
pharmacologic treatment is aimed at slowing down the progression of the disease and lessening
the symptoms. Likewise, there are many nonpharmacological treatments that can also be used to
slow the progression of AD and its clinical manifestations, which include herbal supplements,
probiotics, and dietary and lifestyle changes, however theses therapies are much less studied
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(Mendiola-Precoma et al., 2016). Producing further research on nonpharmacological therapies
can help lessen the symptoms of AD.
The studies portrayed a variety of different herbal supplements with many different
benefits. Most of the herbal supplements showed benefits in improving cognitive function and
neuroprotective effects in individuals with mild-severe AD that was in the early stages of the
disease. Several studies compared solo pharmacological treatment with pharmacological and
nonpharmacological treatments combined, yielding mixed results. One study showed a
significant benefit in the individuals who took both the AChEI and Gingko Biloba (Canevelli et
al., 2014), although the synergistic effect of the agents combined was vague and not fully
explained. Although many of the articles portrayed the same type of benefits with herbal
supplements, many had small sample sizes or were tested on animals, which limits the
applicability of the research, warranting the need for further studies.
Despite the limitations of small sample sizes and animal testing, the current study
provides information on a variety of herbal supplements that have been shown to have some sort
of positive effect on individuals with AD. It shows that herbal supplements have the ability to
successfully treat certain clinical manifestations of this disease process. Additional research on
herbal supplements effectiveness in managing clinical manifestations of AD would be beneficial
to help better validate their uses.
In further studies, the stage of AD and the comparison to pharmacological should be put
into more consideration. In many of the studies, the herbal supplements were compared to a
placebo group. These studies help to show the benefits of herbal supplements, but did not show
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how effective they were in comparison to pharmacological treatment. Comparing herbal
supplement treatment findings to pharmacological treatment findings can demonstrate the
effectiveness of herbal supplements. Comparing the herbal supplements and pharmacologic
treatments can also provide the price differences, dosage sizes, and availability of the agents,
which can be extremely beneficial to individuals with AD. Several of the studies specified the
stage of AD, whereas some of the studies did not. Each stage of AD may respond differently to
herbal supplements, so knowing the stage may be helpful in portraying more accurate and
reliable results. Curcumin blocked the formation of AB plaque in the brain, therefore this herbal
supplement may be beneficial in predementia stages and may be used as a preventative measure
for AD in the future (Anekonda & Reddy, 2005). Finally, combining herbal supplements with
pharmacological treatment may be superior to either treatment alone (Canevelli et al., 2014).
Studies on combining the two treatments may assist in finding the best treatment for AD overall.
When analyzing the studies reviewed, despite limitations, there was a consistency in
findings with certain herbal supplements researched in a multitude of the studies. The herbal
supplements can slow cognitive decline, produce neuroprotective effects, improve ADL’s, and
improve memory function. Studies should be conducted on comparing herbal supplement
effectiveness with pharmacological effectiveness to establish a better understanding of how
beneficial herbal supplements are.
Complementary and alternative therapies are growing in use and can be used in a variety
of disease processes. In specific, herbal supplements provide benefits including anti-psychotic,
anti-inflammatory, anti-depressant, and anti-oxidant properties (Anekonda & Reddy, 2005).
Furthermore, in a specific study comparing an herbal supplement to a pharmacological agent in
20

management of AD, the herbal supplement was found to be less expensive, and easier to come
by (Li et al., 2015). Some individuals are holistic and would prefer to use CAM instead of
pharmacologic therapy, so having it as an option is essential.
In conclusion, there should be further studies on herbal supplement use in controlling
clinical manifestations of AD. Further studies can help to clarify the benefits of herbal
supplements in comparison to pharmacological treatments. However, with the evidence
presented herbal supplements can be safe and effective in treating clinical manifestations of AD
and therefore, should be offered as a treatment option to individuals with AD. In addition,
although a few herbal supplements showed no effect, none of the herbal supplements had a
negative effect on managing the clinical manifestations of AD, suggesting that individuals
should use herbal supplements to better manage their symptoms of AD.

21

Limitations
This literature review contained several limitations. The initial search examined many
different treatments for AD, and therefore did not solely focus on the purpose of this study. Once
a more narrow search was executed, and keywords Alzheimer’s, herbal supplement*, and
benefit* were used, more relevant research was discovered. After excluding AD therapy focused
only with prescriptive agents or others not including herbals, minimal studies were found. These
findings indicate the need for further research in comparing herbal supplement benefits with
pharmacologic treatments on treating the clinical manifestations of AD.
Several of the studies had small sample sizes, were tested on animals, were compared to a
placebo rather than a pharmacological agent, and did not specify what stage of AD the
individuals were in. Animal testing trials have discovered benefits from herbal supplements, but
because mice and rats do not have the same brain capacity and function as a human, human trials
with well-designed clinical trials are needed to determine human benefits. The majority of the
studies focused on elder individuals who had mild-severe AD and used herbal supplements as the
sole treatment for the clinical manifestations of AD. However, for some of the studies it was only
listed that individuals had mild-severe AD. Because every stage of AD is different, it’s important
to know the specific stage the individual is in, so that the research is more reliable. Knowing
what stage of AD and how efficient the herbal supplements worked in that stage will give
individuals a better understanding of when they can use the herbal supplements as a treatment.
The sample sizes ranged from n=26 to n=828. The smallest sample size group was one
of the most important studies which compared Cistanches Herba, Donepezil, and no treatment.
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This study found that Cistanches Herba (herbal supplement) and Donepezil (pharmacologic
agent) showed close to the same improvement in cognitive abilities (Li et al., 2015). This study
provided a significant finding, so it is imperative that future studies involving larger sample sizes
occur. The study with an adequate sample size of n=828 compared alone AChEI treatment to an
AChEI combined with gingko biloba. The combined treatment did show a higher MMSE scored
compared to the alone treatment, however only 29 participants chose to use the combined
treatment, indicating the need of further clarification to understand the effectiveness of
combining therapies (Canevelli et al., 2014). Furthermore, the other studies researched all
showed a positive impact of herbal supplements on controlling the clinical manifestations of AD
aside from one, but due to the small sample sizes further research is required.
Three of the studies in this research were performed on mice or rats. Although cognitive
decline was found to be decreased and many of the herbals studied were found to have
neuroprotective effects and reduce Aβ-induced oxidative stress, the studies were not performed
on a human, making the results inconclusive. Further clinical trials need to be performed on
humans to better understand the benefits of these herbal supplements.
Lastly, many of the clinical trials of herbal supplements were compared to a placebo
group rather than a pharmacological agent. This gives the opportunity to understand the
effectiveness of herbal supplements in managing the clinical manifestations of AD, but without
comparing it to a pharmacological agent, understanding if herbals are as effective as these agents
is difficult. Providing further research in comparing and/or combining the two therapies can be
extremely beneficial to individuals with AD.
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Implications for Nursing
Due to the slow, progressive symptomology of AD, exploring herbal treatment options
for controlling the clinical manifestations of the disease is significant. Herbal supplements can
slow cognitive decline and portray neuroprotective effects, so knowing that AD continuously
gets worse over time, individuals may want to know about this treatment option. Continuing
research on this topic is imperative, so that individuals can receive the most beneficial treatment
for controlling the clinical manifestations of AD.
Individuals with AD and their caregivers should be educated on the various herbal
supplements available as treatment options for the clinical manifestations of AD. Some
individuals prefer complementary and alternative therapies as opposed to pharmacological
treatments, so offering these supplements is essential. Health care facilities should implement
herbal supplements as a complementary or alternative therapy for managing the clinical
manifestations of AD, as there is no research that shows harm from these supplements.
Educating health care providers on this option is important to create adequate patient satisfaction.
Due to numerous limitations throughout the study, further research is needed to
determine how effective herbal supplements are in managing the clinical manifestations of AD.
However with the research presented, herbal supplements can have a positive impact on
managing the clinical manifestations of AD, and combining herbal supplements and
pharmacological therapies can be superior to the use of either solo therapy.
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APPENDIX A: TABLE OF EVIDENCE
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Author(s)
Year
Location

Akhondzadeh et al.
(2010)
Massachusetts

Study Design &
Purpose

Randomized,
placebo controlled
trial
Assess the efficacy
of saffron in the
treatment of mildmoderate AD

Anekonda & Reddy
(2005)
Netherlands

Systemic literature
review
Examined herbal
medicines as a form
of treatment for AD

Sample Size
& Screening
Measures

N= 42
Saffron capsule
(n=22)
Placebo capsule
(n=20)

Results

Saffron produced a
significantly higher
outcome for the
cognitive function
on the ADAS-cog
and CDR tests and
was found safe and
effective.

Protocol was
approved by the
Instituional Review
Board of Tehran
University of
Medical Sciences.

ADAScog: F = 4·12,
d.f. = 1, P = 0·04

Inclusion criteria:
Age 55 and older,
and a baseline
MMSE score of 1526.
This review was
based off of a
survey of PubMed
literature and
included
information from
168 articles

No difference in the
adverse effects was
observed between
the two groups.

It reviews the
current strategies for
treating the clinical
manifestations of
AD with herbal
medicines.

CDR: F = 4·12,
d.f. = 1, P = 0·04

Curcumin was found
to reduce the
accumulation of
Aβ plaques in the
brain.
Ginkgo biloba was
found to protect
spatial cognition
decline.
Dispacus asper
improved cognitive
dysfunction in a
passive avoidance
task.
Ginkgo biloba,
ascorbyl, vitamin E,
pycnogenol, and
palmitate increased
the life span in the
mice.
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Herbal supplement
effectiveness
1=useful
2=inconclusive
3=not useful
1
In this trial, 30
mg/day saffron was
being used on its
own to treat
manifestations of
mild-moderate AD
This study showed
that saffron is safe
and effective in
short term use, but
needs further trials
to validate this
remedy.

2
The studies
reviewed in this
article showed
significant benefits
with the use of
herbal supplements
including decreased
production of
Aβ plaques, less
cognitive decline,
anti-oxidant effects,
and a longer life
span; however these
studies were
performed on mice
and rats.
Herbal drugs have
been found to easily
cross the blood
brain barrier, and

Resveratrol and
centella asitica
improved cognitive
function and
decreased oxidative
stress.
Huperzine A
combined with an
AChEI was found to
increase the
concentration of the
acetylcholine.

are less toxic with
less adverse effects
than
pharmacological
treatments, but need
to be further studied
on humans to
determine the
greatest benefits and
risks.

Green tea extract
worked to reverse
memory deficits by
inhibiting AChEI
activity.

Canevelli et al.
(2014)
London

Prospective
multicenter cohort
study
Evaluates course,
treatment outcomes,
and socioeconomic
status impact on AD
in Europe

N=828
Combined treatment
(n=29)
(Only 29
participants chose to
try out the combined
therapy)
Alone AChEI
treatment
(n=799)
Involved 29 centers
from 12 European
countries all a part
of the European
Alzheimer Disease
Consortium
Inclusion criteria:
Diagnosis of
probable AD,
MMSE score
ranging from 10-26,
living in a
community with a
well-identified
informal caregiver,
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Combined treatment
group showed a
significantly higher
score on the MMSE
compared to the
alone AChEI
treatment group
MMSE mean
differences (followup-baseline)
AChEIs only
-1.44±0.12
AChEIs & Gb
+0.42±0.66
The ADAS-Cog
score also showed
an increase for the
combined treatment
group, however it
was not statistically
significant
No differences in
ADL’s were
observed

1
In this study ginkgo
biloba was
combined with
AChEI’s as
treatment. It was
compared to a group
only taking
AChEI’s for the
treatment of the
clinical
manifestations of
mild-moderate AD.

The group receiving
combined treatment
showed and
confirmed a much
higher MMSE
score, however
because there was
not a significant
difference in the
ADAS-Cog score
and it was a low
number of
participants, the
effectiveness of

Freund et al.
(2014)
Massachusetts

Randomized
placebo controlled
study
Evaluates oral
supplementation of
omega-3 FA’s and
its effects on the FA
in cerebrospinal
fluid

Giulietti et al.
(2016)
United Arab
Emirates

Systemic literature
review
Examines the
effects of nutritional
supplements on the
clinical
manifestations of
AD.

absence of known
conditions reducing
to less than 2 years
the patient’s life
expectancy, and
signed informed
consent
N=33
n-3 FA supplement
(n=18)
Placebo
(n=15)
Ethical committee at
Karolinska
University Hospital
approved the study
protocol.
Inclusion criteria:
Diagnosis of mildmoderate AD,
MMSE score
between 15-30, and
treatment with a
stable dose of
AChEI for at least 3
months before the
study.
Systemic review of
the most recent
literature (129
articles) on the
effects of nutrition
on progression of
AD.
Keywords used in
searches included:
Acetylcholinesterase
inhibitors,
Alzheimer,
antioxidant, metals,
nutritional
supplements,
PUFAs
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ginkgo biloba needs
further clarification.

n-3 FA supplement
group displayed
significant increase
in CSF EPA, DHA,
and n-3 FA levels,
whereas no increase
was observed in the
placebo group.

2

An increase in DHA
in the CSF causes a
greater change in
AD and
inflammatory
biomarkers.

Results show there
may be some form
of preservation of
memory in
individuals with
extremely mild AD,
however the n-3 FA
supplement in
individuals with
moderate-severe
AD has been
unsuccessful.

Vitamin E showed a
neuroprotective role
in mice, but there
was little evidence
of this role in
humans.

2

Fig a polyphenol
was shown to reduce
Aβ and improve
behavioral and
cognitive defects in
AD.
Resveratrol was
tested in mice and
not only helped to
control the cognitive
decline of AD, but
these mice also had
an increase in life
expectancy.

Participants
received a dietary
supplement of n-3
FA to improve the
cognitive decline
caused by mildmoderate AD.

Although the mice
trials showed
beneficial effects on
some of the clinical
manifestations of
AD from these
herbal supplements,
not all have been
tested on humans.
More clinical trials
are needed to define
the benefits of these
herbal supplements.

Ihl et al.
(2011)
New Jersey

Randomized
controlled trial
Tests the efficacy
and safety of a once
a day formulation of
ginkgo biloba in
patients with
dementia with
neuropsychiatric
features

N=404
EGb 761 treatment
(n=202)
Placebo
(n=202)
Protocol was
approved by the
Ethics Committee of
the State
Pharmacology
Centre at the
Ukraine Ministry of
Health. Patients
were recruited at 20
outpatient clinics in
Ukraine
Inclusion criteria:
At least 50 years of
age, and had one of
the following
diagnoses: probable
AD in accordance
with the NINCDSADRDA, possible
AD with
cerebrovascular
disease, or probable
VaD according to
NINDS-AIREN.

Ginkgo biloba was
found to be
ineffective in
preventing AD, but
was found to have
an anti-amyloid
aggregation effect.
Patients treated with
EGb 761 treatment
improved in
cognitive test
performance and
neuropsychiatric
symptoms.
EGb 761 treatment
SKT score improved
by -1.4
NPI total score
improved by -3.2
The placebo group
showed minimal or
no change.
Placebo treatment
SKT score
deteriorated by +0.3
NPI total score did
not change
There was consistent
and statistically
significant outcome
measures for the
EGb 761 treatment
group.

1
This trial included
patients with AD,
vascular dementia
or a mixed form of
dementia.
Participants were
given either 240 mg
of EGb 761, or
placebo both once a
day for 24 weeks.
Primary outcome
measures were the
SKT score and the
12 item NPI score.
Secondary outcome
measures included
the NPI caregiver
stress score, the
ADCS-CGIC score,
the ADL-IS score,
the DEMQOLProxy scale, and the
Verbal Fluency test.
Participants
receiving the EGb
761 showed
improvement in
both primary
measures whereas
the placebo group
showed minimal to
no change in the
primary measures.
Secondary outcome
measures also
showed superiority
in the EGb 761
treatment group
compared to the
placebo group.
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Li et al.
(2015)
China

Randomized
placebo controlled
study
Investigates the
potential of
Cistanches Herbal
to have
neuroprotective
effects for moderate
AD

N=26
Cistanches Herbal
capsule
(n=11)
Donepezil
(n=9)

Cistanches Herba
can improve
cognitive abilities in
AD and slow down
hippocampus
atrophy, suppress Ttau, TNF-a, and
IL1B in CSF in AD

No treatment
(n=6)
26 participants were
chosen from the
second and fifth
affiliated hospital of
Zhengzhou
University from
2013-2014.

Qualitative
ethnographic study
Evaluates both
pharmacological
and
nonpharmacological
treatments and their
effects on treating

Combines own
research and other
research articles.
Studies throughout
the article were
based on
observation of either
human or mice.
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In this trial there
were 3 different
groups being
compared.
Participants had AD
and were either
given the
supplement
Cistanches Herbal,
donepezil, which is
an AChEI, or no
treatment at all.
At 24 weeks there
was no significant
difference between
the 3 groups
cognitive abilities,
however by the 48th
week there were
changes.

Inclusion criteria:
MMSE and ADASscores from 10-20
and 29-40

Mendiola-Precoma
et al.
(2016)
New York

1

Pharmacological
treatment: AChEI’s
were shown to
improve memory
loss and are well
tolerated. NMDA’s
are approved in
mild-moderate AD
for cognition.

Both the Cistanches
Herbal group and
the Donepezil group
showed
improvement,
however they
showed about the
same improvement
as each other.
Cistanches Herbal
was shown to be
much cheaper and
easier to retrieve
than donepezil, so
because they
showed about the
same outcomes,
some individuals
may prefer this herb
over donepezil.
1
This study suggests
combining
pharmacological
treatments with 2 or
more
nonpharmacological
treatments,

clinical
manifestations of
AD

Mi Hye
(2014)
Korea

Qualitative
ethnographic study
This research article
was designed to
investigate the
effectiveness of
certain herbs on
cognitive
impairment in AD.

Muscarinic and
Nicotinic Ach
receptors along with
histamine receptors
have the potential to
be beneficial in
treatment of clinical
manifestations of
AD, but need further
research.

Combines own
research and other
research articles.
Studies throughout
the article were
based on
observation of either
human or mice.
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Nonpharmacological
treatments: Exercise
and mental
challenges have
preventive benefits
for AD. Herbal
supplements studied
included flavonoids,
alkaloids,
terpenoids, ginkgo
biloba, and
polyphenols.
Resveratrol is a
polyphenol and was
found to have
neuroprotective
effects on AD.
Flavonoids are
considered safe and
have also been
found to have
neuroprotective
effects on AD.
Ginkgo biloba is
shown to help
memory function in
AD.
Berberine is an herb
that may improve
cognitive
impairment and
decrease Aβ
production.
Curcumin was
shown to improve
spontaneous
behavior and better
recognize memory
tasks.

including herbal
supplements such as
ginkgo biloba,
resveratrol, and
flavonoids can be
most beneficial in
controlling the
clinical
manifestations of
AD.

2
The majority of
these herbs benefits
were shown through
studies on mice or
rats, making it an
inconclusive
conclusion for the
benefits for humans.

Ginsenoside Rg1
was shown to block
Aβ induced neuronal
injury and
demonstrated
neuroprotective
effects.
Puerarin was shown
to decrease Aβinduced cell death.

Perry et al.
(1998)
New York

Qualitative
ethnographic study
This study examines
different methods
and herbal
supplements used in
different countries
to treat the clinical
manifestations of
AD.

Combines own
research and other
research articles.
Studies throughout
the article were
based on
observation and
statistics from
humans.

Silibinin is thought
to improve
recognition memory
and protect against
Aβ-induced
oxidative stress.
Ginkgo biloba was
proven to improve
cognitive function in
mild-moderate AD.
Balm essential oil
combined with
lavender showed a
slight increase in
general functioning
in a small number of
patients with
dementia.
For centuries, sage
is shown to have
memory
enhancement and
promote calmness.
A Chinese medicine
known as Salvia was
reported to be
effective in memory
function in 40% of
patients with AD.

Posadzki et al.
(2012)
Massachusetts

Literature review
Evaluates the
literature on
complementary and

225 articles were
considered, however
a systemic review of
6 articles on 4 data
bases from their

32

Ancient Greeks used
rosemary to
stimulate memory.
Only 6 articles met
the inclusion
criteria. Based on
these articles, the
evidence to support

1
This article
examines many
different traditions
from around the
world. Although
some of these
treatments weren’t
on patients with
AD, these herbs
were still shown to
improve memory
which is one of the
main clinical
manifestations of
AD. These herbs
have been around
for ages, and should
be further
researched to clarify
exactly what they
are capable of.

2
Some of the herbal
supplements
reviewed in this

alternative medicine
for AD

inception until May
2011 were used.
MEDLINE,
EMBASE, AMED
and the Cochrane
Library were
searched

Wang et al.
(2015)
United States

Randomized
controlled study
Investigates the
effects of a
combination of
nutrients in APPPSN in mouse
model of AD

Inclusion criteria:
reporting and
comprehensiveness
of searches,
repeatable eligibility
criteria, avoidance
of selection bias,
presence of a
validity assessment
tool, robustness of
data analysis and
supportiveness of
conclusions.
N=96
Double transgenic
mice
(n=72)
Wild-type
littermates
(n=24)
Study protocol was
approved by the
Medical Ethics
Committee of
Harbin Medical
University
Inclusion criteria:
Mice purchased
from the Model
Animal Resource
Platform of Nanjing
University,
acclimatized for 1
week

CAM for the
treatment of AD is
unclear.
As some herbal
medicines show a
promise in
managing AD,
future research is
defensible.

Mice given the
nutrient combination
had significantly
lower B-amyloid
peptide
accumulation and a
greater antioxidant
capacity. The
nutrient combination
mice also had higher
behavioral test
scores.

literature review
included lemon
balm, sage, ginkgo
biloba, lycopodium
serratum, and panaz
ginseng.
Out of these herbal
supplements ginkgo
biloba and ginseng
were shown to
improve cognitive
function and quality
of life, however
were only compared
to placebo and not
current drug therapy
for AD.

2

This study included
one group of mice
receiving their
normal feeding and
another group of
mice receiving
added dietary
supplements in their
food.
The group receiving
extra dietary
supplements
showed
improvement
concluding that
these supplements
could be considered
as a strategy to slow
cognitive decline in
AD.
This study was done
in mice therefore,
more research needs
to be done to prove
the effectiveness of
the dietary
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supplements in this
study.

Yang et al.
(2014)
New Jersey

Systemic review in
randomized
controlled trials
Evaluate the
efficacy of natural
medicines for the
treatment of AD

Systemic review of
literature published
from 1950 through
July 2013.
MEDLINE,
EMBASE, the
Cochrane Library,
and PSYCHINFO
were searched.
Inclusion criteria:
Published, double
blind randomized,
placebo-controlled
studies, diagnostic
criteria of AD from
either DSM or
NINCDS-ADRDA,
and comparisons of
natural medicines to
placebo or orthodox
medications.

21 clinical reports fit
the inclusion
criteria. Many
natural medicines
had minimal
benefits, but ginkgo
biloba showed to
have better
outcomes compared
to the placebo for
both cognitive being
and activities of
daily living.

1
This review
discussed herbal
supplements
including sage,
lemon balm, crocus,
curcumin, huperzine
Fuzhisan, and
ginkgo biloba.
Crocus, sage, lemon
balm, and Fuzhisan
were found to
improve cognitive
function through the
ADAS-Cog test.
These were all
compared to a
placebo group and
were not compared
to AD drug therapy.
Huperzine and
curcumin showed
no significant
improvement in
cognitive function
in individuals with
AD.
Ginkgo biloba was
shown to have a
positive effect on
cognitive function
and activities of
daily living in 5 out
of the 6 articles that
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Zeng et al.
(2015)
Pennsylvania

Systemic review in
randomized
controlled trials
Evaluate the
effectiveness and
safety of Chinese
herbal medicine for
kidney nourishment
(CHMK) in patients
with AD

7 medical databases
were searched from
their inception to
July 19, 2014.

Inclusion criteria:
Citations reviewed,
risk of bias
assessed, and data
extracted
independently
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20 studies were
included in the
meta-analysis and
none were able to
show the safety or
effectiveness of
CHMK.
Bias and low quality
trials prove the need
for further studies to
define the role of
CHMK in AD.

focused on this
herb.
1
This article
compared the oral
administration of
CHMK plus normal
pharmacotherapy
with
pharmacotherapy
used by itself.
The safety
effectiveness of
CHMK is not able
to be determined by
this study because
of small sizes and
poorly designed
studies.

APPENDIX B: FIGURE 1
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Potential relevant citations identified after screening data bases.
(CINAHL, ERIC, Ebsco Host, Medline, and PsychINFO)
n=72

Excluded through
inclusion
materials not
being met.
n=49

Studies and Articles retrieved for further review
n=35

Studies and articles
excluded following in
depth analysis;
concluding they did
not meet criteria.
n=27
Studies and articles that encumbered
inclusion criteria
n=23

Additional studies and articles were reviewed and hand
selected that met inclusion criteria making a total of:
n=14
Key Search Terms: Alzheimer’s, dementia*, herbal supplement*, clinical manifestation*, symptom*,
benefit*, and risk*
Limiters: English language, peer reviewed, published 1995-2016
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